A new area of cancer immunotherapy is enhancing therapeutic mAb-mediated CD16 activation of NK cells. CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other ...

NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...

Although NK cells have natural antibody-binding molecules such as CD16, their ability to hold onto antibodies long-term is inferior compared with CD64. To improve antibody binding, the researchers ...

Although NK cells have natural antibody-binding molecules such as CD16, their ability to hold onto antibodies long-term is inferior compared with CD64. To improve antibody binding, the researchers ...

The bispecifics are differentiated through their targeting of NKp46 to engage NK cells, rather than the CD16 and NKG2D receptors targeted by other bispecifics. Importantly, NKp46 expression is ...

SAR443579 (also known as IPH6101) is a tri-functional NKp46/CD16-based anti-CD123 NK cell engager – described as a first-in-class therapy – that has now advanced into a phase 2 programme.

CD16 iPSC-derived NK (iNK) cell – Fate’s lead iPSC-derived cancer immunotherapy is a targeted iNK cell product created from a master engineered pluripotent cell line that expresses a high ...

“RMAT designation for Anktiva combined with NK cells was applied for by the Founder in the initial ... express both a PD-L1–targeted CAR and the high-affinity variant of CD16 would result in potent ...